Pharmacokinetic-guided dose reduction of emicizumab in congenital hemophilia A: interim analysis of the DosEmi study

This publication has 28 references indexed in Scilit:

• Low-dose emicizumab prophylaxis in patients with severe hemophilia A: a retrospective study bringing new hope for our patients
  Journal of Thrombosis and Haemostasis, 2023
• The efficacy of the entire-vial dosing of emicizumab: Real-world evidence on plasma concentrations, bleeds, and drug waste
  Research and Practice in Thrombosis and Haemostasis, 2023
• Quantification of emicizumab by mass spectrometry in plasma of people with hemophilia A: A method validation study
  Research and Practice in Thrombosis and Haemostasis, 2022
• Pharmacokinetics and Associated Efficacy of Emicizumab in Humans: A Systematic Review
  Clinical Pharmacokinetics, 2021
• Haemophilia
  Nature Reviews Disease Primers, 2021
• Emicizumab Dosing in Children and Adults with Hemophilia A: Simulating a User-Friendly and Cost-Efficient Regimen
  Thrombosis and Haemostasis, 2021
• Exposure–Bleeding Count Modeling of Emicizumab for the Prophylaxis of Bleeding in Persons with Hemophilia A with/Without Inhibitors Against Factor VIII
  Clinical Pharmacokinetics, 2021
• Population Pharmacokinetic Analysis and Exploratory Exposure–Bleeding Rate Relationship of Emicizumab in Adult and Pediatric Persons with Hemophilia A
  Clinical Pharmacokinetics, 2020
• Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
  New England Journal of Medicine, 2018
• A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A
  Clinical Pharmacokinetics, 2017